Part 3.15 / M35 (Part 6/6)
3. PART 3: HARMONISED CLASSIFICATION AND LABELLING TABLE
|
Index No |
►M18 Chemical name ◄ |
EC No |
CAS No |
Classification |
Labelling |
Notes |
||||
|
Hazard Class and Category Code(s) |
Hazard statement Code(s) |
Pictogram, Signal Word Code(s) |
Hazard statement Code(s) |
Suppl. Hazard statement Code(s) |
||||||
|
607-034-00-0 |
methyl acrylate; methyl propenoate |
202-500-6 |
Flam. Liq. 2 Acute Tox. 3 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 |
H225 H331 H312 H302 H335 H315 H319 H317 |
GHS02 GHS06 Dgr |
H225 H331 H312 H302 H335 H315 H319 H317 |
|
inhalation: ATE = 3 mg/L (vapours) dermal: ATE = 1 100 mg/kg bw oral: ATE = 500 mg/kg bw |
D |
|
|
607-223-00-8 |
transfluthrin (ISO); 2,3,5,6-tetrafluorobenzyl (1R,3S)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate |
405-060-5 |
Carc. 2 Acute Tox. 4 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H302 H370 (nervous system) H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H302 H370 (nervous system) H410 |
EUH066 |
oral: ATE = 580 mg/kg bw M = 1 000 M = 1 000 |
|
|
|
607-246-00-3 |
allyl methacrylate; 2-methyl-2-propenoic acid 2-propenyl ester |
202-473-0 |
Flam. Liq. 3 Acute Tox. 2 Acute Tox. 3 Acute Tox. 4 Aquatic Acute 1 |
H226 H330 H311 H302 H400 |
GHS02 GHS06 GHS09 Dgr |
H226 H330 H311 H302 H400 |
|
inhalation: ATE = 1,5 mg/L (vapours) dermal: ATE = 300 mg/kg bw oral: ATE = 400 mg/kg bw |
|
|
|
607-766-00-0 |
tetramethylene dimethacrylate |
218-218-1 |
Skin Sens. 1B |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
|
607-767-00-6 |
7,7,9(or 7,9,9)-trimethyl–4,13-dioxo–3,14-dioxa–5,12-diazahexadecane–1,16-diyl bismethacrylate |
276-957-5 |
Skin Sens. 1B |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
|
607-768-00-1 |
2,2'-ethylenedioxydiethyl dimethacrylate |
203-652-6 |
Skin Sens. 1B |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
|
607-769-00-7 |
bifenox (ISO); methyl 5-(2,4-dichlorophenoxy)-2-nitrobenzoate |
255-894-7 |
Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
oral: ATE = 1 500 mg/kg bw M = 1 000 M = 1 000 |
|
|
|
612-004-00-5 |
triethylamine |
204-469-4 |
Flam. Liq. 2 Acute Tox. 3 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1A Eye Dam. 1 |
H225 H331 H311 H301 H314 H318 |
GHS02 GHS06 GHS05 Dgr |
H225 H331 H311 H301 H314 |
|
inhalation: ATE = 7,2 mg/L (vapours) dermal: ATE = 300 mg/kg bw oral: ATE = 100 mg/kg bw STOT SE 3; H335: C ≥ 1 % |
|
|
|
612-049-00-0 |
di-n-butylamine |
203-921-8 |
Flam. Liq. 3 Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1B Eye Dam. 1 |
H226 H330 H311 H301 H314 H318 |
GHS02 GHS06 GHS05 Dgr |
H226 H330 H311 H301 H314 |
EUH 071 |
inhalation: ATE = 1,2 mg/L (vapours) dermal: ATE = 300 mg/kg bw oral: ATE = 220 mg/kg bw |
|
|
|
612-056-00-9 |
N,N-dimethyl-m-toluidine; [1] N,N-dimethyl-o-toluidine [2] |
204-495-6 [1] 210-199-8 [2] |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 |
H331 H311 H301 H373 ** H412 |
GHS06 GHS08 Dgr |
H331 H311 H301 H373 ** H412 |
|
* |
C |
|
|
612-295-00-9 |
benfluralin (ISO); N-butyl-N-ethyl-α,α,α-trifluoro-2,6-dinitro-p-toluidine |
217-465-2 |
Carc. 2 Repr. 2 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H361d H315 H319 H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H361d H315 H319 H317 H410 |
|
M = 10 M = 10 |
|
|
|
612-296-00-4 |
N,N-dimethyl-p-toluidine |
202-805-4 |
Carc. 1B Acute Tox. 4 Acute Tox. 3 STOT RE 2 Aquatic Chronic 3 |
H350 H332 H301 H373 (blood system, respiratory tract) H412 |
GHS08 GHS06 Dgr |
H350 H332 H301 H373 (blood system, respiratory tract) H412 |
|
inhalation: ATE = 1,4 mg/L (dusts or mists) oral: ATE = 140 mg/kg bw |
|
|
|
612-297-00-X |
1-phenylethan-1-one (1-phenylethylidene)hydrazone |
211-979-0 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
|
612-298-00-5 |
1,4-Benzenediamine, N,N’-mixed Ph and tolyl derivs.; |
273-227-8 |
Repr. 1B Skin Sens. 1 |
H360FD H317 |
GHS08 GHS07 Dgr |
H360FD H317 |
|
|
|
|
|
613-088-00-6 |
1,2-benzisothiazol-3(2H)-one; 1,2-benzisothiazolin-3-one |
220-120-9 |
Acute Tox. 2 Acute Tox. 4 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 |
H330 H302 H315 H318 H317 H400 H410 |
GHS06 GHS05 GHS09 Dgr |
H330 H302 H315 H318 H317 H410 |
|
inhalation: ATE = 0,21 mg/L (dusts or mists) oral: ATE = 450 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,036 % M = 1 M = 1 |
|
|
|
613-127-00-7 |
mepiquat chloride (ISO); 1,1-dimethylpiperidinium chloride |
246-147-6 |
Acute Tox. 4 Acute Tox. 3 Aquatic Chronic 3 |
H332 H301 H412 |
GHS06 Dgr |
H332 H301 H412 |
|
inhalation: ATE = 2,8 mg/L (dusts or mists) oral: ATE = 270 mg/kg bw |
|
|
|
613-307-00-5 |
clothianidin (ISO); (E)-1-(2-chloro–1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidine |
433-460-1 |
Repr. 2 Acute Tox. 4 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361f H302 H370 (nervous system) H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H361f H302 H370 (nervous system) H410 |
|
oral: ATE = 390 mg/kg bw M = 10 M = 100 |
|
|
|
613-346-00-8 |
4-nitrosomorpholine |
— |
Carc. 1B Muta. 2 STOT RE 1 |
H350 H341 H372 (liver) |
GHS08 Dgr |
H350 H341 H372 (liver) |
|
Carc. 1B; H350: C ≥ 0,001 % |
|
|
|
613-347-00-3 |
difenoconazole (ISO); 1-({2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl–1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazole; 3-chloro-4-[(2RS,4RS;2RS,4SR)-4-methyl-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]phenyl 4-chlorophenyl ether |
— |
Carc. 2 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H302 H319 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H302 H319 H410 |
|
oral: ATE = 1 450 mg/kg bw M = 10 M = 10 |
|
|
|
613-348-00-9 |
9-[2-(ethoxycarbonyl)phenyl]–3,6-bis(ethylamino)–2,7-dimethylxanthylium chloride; Basic Red 1 |
213-584-9 |
Acute Tox. 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H301 H318 H317 H400 H410 |
GHS06 GHS05 GHS09 Dgr |
H301 H318 H317 H410 |
|
oral: ATE = 280 mg/kg bw M = 10 M = 1 |
|
|
|
613-349-00-4 |
4-methylimidazole |
212-497-3 |
Carc. 1B Repr. 1B |
H350 H360Fd |
GHS08 Dgr |
H350 H360Fd |
|
|
|
|
|
615-051-00-X |
3,3'-dimethylbiphenyl–4,4'-diyl diisocyanate |
202-112-7 |
Carc. 2 Resp. Sens. 1 Skin Sens. 1A |
H351 H334 H317 |
GHS08 Dgr |
H351 H334 H317 |
|
Skin Sens. 1A; H317: C ≥ 0,001 % |
|
|
|
616-035-00-5 |
cymoxanil (ISO); 2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; [1] (2E)-2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; [2] |
261-043-0 [1] - [2] |
57966-95-7 [1] 166900-80-7 [2] |
Repr. 2 Acute Tox. 4 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361fd H302 H373 (blood system, thymus, eyes) H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H361fd H302 H373 (blood system, thymus, eyes) H317 H410 |
|
oral: ATE = 360 mg/kg bw M = 1 M = 1 |
|
|
616-104-00-X |
benalaxyl (ISO); methyl N-(2,6-dimethylphenyl)-N-(phenylacetyl)-DL-alaninate |
275-728-7 |
Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
oral: ATE = 1 000 mg/kg bw M = 1 M = 1 |
|
|
|
616-241-00-5 |
foramsulfuron (ISO); 2-{[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl}-4-formamido-N,N-dimethylbenzamide; 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-dimethylcarbamoyl-5-formamidophenylsulfonyl)urea |
— |
Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H400 H410 |
GHS08 GHS09 Wng |
H351 H410 |
|
M = 1 000 M = 100 |
|
|
|
616-242-00-0 |
picolinafen (ISO); N-(4-fluorophenyl)-6-[3-(trifluoromethyl)phenoxy]pyridine-2-carboxamide; 4′-fluoro-6-[(α,α,α-trifluoro-m-tolyl)oxy]picolinanilide |
— |
STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H373 (blood system, thyroid) H400 H410 |
GHS08 GHS09 Wng |
H373 (blood system, thyroid) H410 |
|
M = 1 000 M = 1 000 |
|
|